<?xml version="1.0" encoding="UTF-8"?>
<akomaNtoso xmlns="http://docs.oasis-open.org/legaldocml/ns/akn/3.0">
  <act name="PBH">
    <meta>
      <identification source="#ny-legislature">
        <FRBRWork>
          <FRBRthis value="/akn/us-ny/act/pbh/section-265-B"/>
          <FRBRuri value="/akn/us-ny/act/pbh/section-265-B"/>
          <FRBRdate date="2021-04-23" name="enacted"/>
          <FRBRauthor href="#ny-legislature"/>
          <FRBRcountry value="us-ny"/>
          <FRBRnumber value="265-B"/>
          <FRBRname value="PBH"/>
        </FRBRWork>
        <FRBRExpression>
          <FRBRthis value="/akn/us-ny/act/pbh/section-265-B/eng@2025-12-31"/>
          <FRBRuri value="/akn/us-ny/act/pbh/section-265-B/eng@2025-12-31"/>
          <FRBRdate date="2025-12-31" name="publication"/>
          <FRBRauthor href="#arch"/>
          <FRBRlanguage language="eng"/>
        </FRBRExpression>
        <FRBRManifestation>
          <FRBRthis value="/akn/us-ny/act/pbh/section-265-B/eng@2025-12-31/main.xml"/>
          <FRBRuri value="/akn/us-ny/act/pbh/section-265-B/eng@2025-12-31/main.xml"/>
          <FRBRdate date="2025-12-31" name="generation"/>
          <FRBRauthor href="#arch"/>
        </FRBRManifestation>
      </identification>
      <references source="#arch">
        <TLCOrganization eId="arch" href="https://cosilico.ai" showAs="Cosilico Arch"/>
        <TLCOrganization eId="ny-legislature" href="https://legislation.nysenate.gov" showAs="New York State Legislature"/>
      </references>
    </meta>
    <body>
      <section eId="sec_265_B">
        <num>265-B</num>
        <heading>Funding committee</heading>
        <subsection eId="sec_265_B__subsec_a">
          <num>(a)</num>
          <content>
            <p>provide for an independent scientific peer review committee\ncomposed of individuals with expertise in the field of biomedical\nresearch who shall review grant applications based on the criteria\nrequirements and standards adopted by the funding committee, and make\nrecommendations to the funding committee for the award of grants;\n</p>
          </content>
        </subsection>
        <subsection eId="sec_265_B__subsec_b">
          <num>(b)</num>
          <content>
            <p>develop criteria including an appropriate competitive scoring\nmethod, standards, and requirements for considering funding applications\nand for awarding research grants, including but not limited to\nrecommendations for the overhead/indirect component of such grants for\nthe development and submission of funding applications by New York state\nbased consortia;\n</p>
          </content>
        </subsection>
        <subsection eId="sec_265_B__subsec_c">
          <num>(c)</num>
          <content>
            <p>recommend standards for the scientific and medical oversight of\nawards;\n</p>
          </content>
        </subsection>
        <subsection eId="sec_265_B__subsec_d">
          <num>(d)</num>
          <content>
            <p>solicit through requests for proposals and otherwise, and to\naccept proposals for research projects including grant applications;\n</p>
          </content>
        </subsection>
        <subsection eId="sec_265_B__subsec_e">
          <num>(e)</num>
          <content>
            <p>review grant applications based on the criteria, requirements, and\nstandards adopted by the funding committee utilizing a process that\ngives due consideration to the amount of nonpublic funds contributed by\nthe project sponsor, including cash, in-kind personnel, equipment or\nmaterials, donations, the opportunity to leverage funds, including\nfederal, private and not-for-profit funds reasonably anticipated to be\nreceived by the project sponsors; provided, however, that nonpublic\nfunds shall only be considered as a factor by the funding committee when\nreviewing applications of equivalent merit as determined by the\nindependent scientific peer review committee;\n</p>
          </content>
        </subsection>
        <subsection eId="sec_265_B__subsec_f">
          <num>(f)</num>
          <content>
            <p>make recommendations to the commissioner for the award of research\ntherapy development and clinical trial grants; and\n</p>
          </content>
        </subsection>
        <subsection eId="sec_265_B__subsec_g">
          <num>(g)</num>
          <content>
            <p>recommend standards for the evaluation of grantees to ensure that\nthey comply with all applicable requirements, including, but not limited\nto, conducting peer group progress oversight reviews of grantees to\nensure compliance with the terms of the award and report to the\ncommissioner any recommendations or subsequent action. Such standards\nshall mandate periodic reporting by grantees.\n  3. With the exception of the ex officio member, the funding committee\nshall be divided into three classes. Of the three classes, the first\nclass appointed shall include three of the governor's appointees, one\nappointee nominated by the temporary president of the senate, and one\nappointee nominated by the speaker of the assembly and shall serve for a\nterm ending one year from the effective date of this title. The second\nclass shall include two of the governor's appointees, one appointee\nnominated by the minority leader of the senate, and one appointee\nnominated by the minority leader of the assembly and shall serve for a\nterm ending two years from the effective date of this title. The third\nclass shall include the final governor's appointee, one appointee\nnominated by the temporary president of the senate, and one appointee\nnominated by the speaker of the assembly; and shall serve for a term\nending three years from the effective date of this title. Subsequently,\neach member appointed shall serve a term of three years and no more than\ntwo terms of three years each. A vacancy in the membership of the board\nshall be filled for the unexpired portion of the term in the same manner\nas the original appointment.\n  * NB Repealed December 31, 2025\n</p>
          </content>
        </subsection>
      </section>
    </body>
  </act>
</akomaNtoso>